Utah Medical Products Inc

Utah Medical Products Inc(UTMD)股票分析

$71.760

+0.639 (+0.89%)收盤時

Loading chart…
High
72.280
Open
70.580
VWAP
71.53
Vol
14.25K
Mkt Cap
235.88M
Low
70.550
Amount
1.02M
EV/EBITDA, TTM
0.00

Utah Medical Products, Inc. manufactures and markets a range of specialty medical devices. The Company’s range of products includes those used in critical care areas and the labor and delivery departments of hospitals, as well as outpatient clinics and physicians offices. Its products are sold directly to end-user facilities in the United States, Ireland, United Kingdom, Canada, France and Australia, and through third party distributors in other outside the United States (OUS) markets. It offers fetal monitoring accessories. Its specialized labour and delivery tools include BT-Cath, CVX-Ripe, AROM-COT, MUC-X, and Cordguard. The Company’s vacuum-assisted delivery (VAD) systems include CMI soft silicone bell-shaped birthing cups and reusable hand-held vacuum pumps, which are the safest products available for use in vacuum-assisted operative deliveries. Its neonatal intensive care products include Disposa-Hood and GESCO. It also distributes harm-reduction medical devices.

AI analysis of Utah Medical Products Inc (UTMD)

buy

Utah Medical Products Inc is a good buy right now due to its current price of $72.77, which is supported by a solid forward P/E ratio of 13.04, indicating attractive valuation compared to future earnings. Additionally, the company has shown a year-to-date change of +28.80%, reflecting strong momentum. However, a risk to consider is the recent revenue decline of 10.2% year-over-year, which could impact future performance.

估值指標

The current forward P/E ratio for Utah Medical Products Inc (UTMD) is 13.04, compared to its 5-year average forward P/E of 1.75.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.75
Current P/E
13.04
高估
6.20
低估
-2.71

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for UTMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%UTMD

$61.55

情境價格

B

Base

Base · 50%UTMD

$52.40

情境價格

B

Bear

Bear · 25%UTMD

$44.83

情境價格

事件時間軸

2026-08-31 (ET)

09:30:00

Femcare Acquires Orion Medical Supplies in the UK

2026-07-23 (ET)

09:30:00

Company Reports Q2 Revenue of $8.5M

2026-04-23 (ET)

09:10:00

Q1 Revenue Reports $8.72M vs. $9.71M Last Year

2026-01-29 (ET)

09:10:00

Company Reports Q4 Revenue of $9.04M

2025-11-04 (ET)

10:06:12

Utah Medical Products Increases Quarterly Cash Dividend by 1.6% to $0.31 per Share

資訊

UTMD FAQ — answered by Alphio AI

Utah Medical Products, Inc. manufactures and markets a range of specialty medical devices. The Company’s range of products includes those used in critical care areas and the labor and delivery departments of hospitals, as well as outpatient clinics and physicians offices. Its products are sold directly to end-user facilities in the United States, Ireland, United Kingdom, Canada, France and Australia, and through third party distributors in other outside the United States (OUS) markets. It offers fetal monitoring accessories. Its specialized labour and delivery tools include BT-Cath, CVX-Ripe, AROM-COT, MUC-X, and Cordguard. The Company’s vacuum-assisted delivery (VAD) systems include CMI soft silicone bell-shaped birthing cups and reusable hand-held vacuum pumps, which are the safest products available for use in vacuum-assisted operative deliveries. Its neonatal intensive care products include Disposa-Hood and GESCO. It also distributes harm-reduction medical devices. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Utah Medical Products Inc is a good buy right now due to its current price of $72.77, which is supported by a solid forward P/E ratio of 13.04, indicating attractive valuation compared to future earnings. Additionally, the company has shown a year-to-date change of +28.80%, reflecting strong momentum. However, a risk to consider is the recent revenue decline of 10.2% year-over-year, which could impact future performance.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始